Senti Biosciences Inc. [SNTI] is -61.82% lower this YTD. Is it still time to buy?

Senti Biosciences Inc. [NASDAQ: SNTI] stock went on a downward path that fall over -3.45% on Monday, amounting to a one-week price increase of more than 2.27%.

Over the last 12 months, SNTI stock dropped by -74.80%. The one-year Senti Biosciences Inc. stock forecast points to a potential upside of 87.5. The average equity rating for SNTI stock is currently 3.00, trading closer to a bullish pattern in the stock market.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The market cap for the stock reached $11.53 million, with 45.70 million shares outstanding and 27.77 million shares in the current float. Compared to the average trading volume of 128.60K shares, SNTI stock reached a trading volume of 8155719 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Senti Biosciences Inc. [SNTI]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SNTI shares is $2.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SNTI stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Senti Biosciences Inc. shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on October 07, 2022.

The Average True Range (ATR) for Senti Biosciences Inc. is set at 0.03, with the Price to Sales ratio for SNTI stock in the period of the last 12 months amounting to 9.08. The Price to Book ratio for the last quarter was 0.21, with the Price to Cash per share for the same quarter was set at 0.52.

SNTI Stock Performance Analysis:

Senti Biosciences Inc. [SNTI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.27. With this latest performance, SNTI shares dropped by -30.83% in over the last four-week period, additionally sinking by -39.84% over the last 6 months – not to mention a drop of -74.80% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SNTI stock in for the last two-week period is set at 37.05, with the RSI for the last a single of trading hit 37.44, and the three-weeks RSI is set at 38.34 for Senti Biosciences Inc. [SNTI]. The present Moving Average for the last 50 days of trading for this stock 0.3195, while it was recorded at 0.2484 for the last single week of trading, and 0.3999 for the last 200 days.

Insight into Senti Biosciences Inc. Fundamentals:

Senti Biosciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.79 and a Current Ratio set at 5.79.

Senti Biosciences Inc. [SNTI] Institutonal Ownership Details

The top three institutional holders of SNTI stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in SNTI stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in SNTI stock with ownership which is approximately 5.8386%.